Attached files
file | filename |
---|---|
EX-99.3 - PRESENTATION - AzurRx BioPharma, Inc. | ex99-3.htm |
EX-99.1 - PRESS RELEASE - AzurRx BioPharma, Inc. | ex99-1.htm |
EX-5.1 - OPINION - AzurRx BioPharma, Inc. | ex5-1.htm |
EX-4.1 - FORM OF WARRANT - AzurRx BioPharma, Inc. | ex4-1.htm |
EX-1.1 - UNDERWRITING AGREEMENT - AzurRx BioPharma, Inc. | ex1-1.htm |
8-K - CURRENT REPORT - AzurRx BioPharma, Inc. | azrx8k_may12018.htm |
Exhibit 99.2
AzurRx BioPharma Announces Pricing of $10.4
Million Public Offering of Common Stock
Brooklyn,
NY - (GLOBE NEWSWIRE) May 1, 2018 – AzurRx BioPharma (NASDAQ:
AZRX), (“AzurRx” or the
“Company”), today announced the pricing of an
underwritten public offering of 4,160,000 shares of its common
stock at an offering price of $2.50 per share. The gross proceeds
of the offering are expected to be approximately $10.4 million,
before deducting the underwriting discount and other estimated
offering expenses.
Oppenheimer & Co. Inc. is acting as sole underwriter for the
offering.
The closing of the offering is expected to occur on or about May 3,
2018, subject to the satisfaction of customary closing
conditions.
AzurRx currently intends to use the net proceeds from the
offering primarily for research and development expenses
associated with its continuing clinical development and testing of
MS1819, advancing its preclinical programs for AZX1103 and for
other general corporate purposes and capital
expenditures.
The offering is being conducted pursuant to the Company’s
shelf registration statement on Form S-3 (File No. 333-221275)
previously filed with and subsequently declared effective by the
Securities and Exchange Commission (the SEC) on November 17,
2017 and an additional registration statement filed pursuant
to Rule 462(b) that was declared effective when filed. A final
prospectus supplement and an accompanying prospectus relating to
the offering will be filed with the SEC and
will be available on the SEC’s website located at
http://www.sec.gov.When available,
electronic copies of the final prospectus supplement and the
accompanying prospectus relating to the offering may be obtained
from: Oppenheimer & Co. Inc., Attention: Syndicate Prospectus
Department, 85 Broad St., 26th Floor,
New York, NY 10004, by telephone at (212) 667-8563 or by email at
EquityProspectus@opco.com.
Before investing in the offering, you should read in their entirety
the prospectus supplement and the accompanying prospectus and the
other documents that AzurRx has filed with the SEC that are
incorporated by reference in the prospectus supplement and the
accompanying prospectus, which provide more information about
AzurRx and the offering.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities described herein,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction. The
offering will be made only by means of a prospectus that forms a
part of the registration statement.
About AzurRx
AzurRx
BioPharma, Inc. (NASDAQ:AZRX) is engaged in the research and
development of non-systemic biologics for the treatment of patients
with gastrointestinal disorders. MS1819 recombinant lipase for
exocrine pancreatic insufficiency is the company's lead development
program, and additional early stage research is being conducted for
the prevention of certain hospital-acquired infections. The company
is headquartered in Brooklyn, NY, with scientific operations based
in Langlade, France. Additional information on the company can be
found at www.azurrx.com
Forward-Looking Statements
This
press release contains forward-looking statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical facts
contained in this press release are forward-looking statements,
including statements regarding the Company’s expectations on
the completion, timing and size of the proposed public offering and
the anticipated use of proceeds therefrom. In some cases, you can
identify forward-looking statements by terms such as "may," "will,"
"should," "expect," "plan," "anticipate," "could," "intend,"
"target," "project," "contemplates," "believes," "estimates,"
"predicts," "potential" or "continue" or the negative of these
terms or other similar expressions. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions,
including the risks and uncertainties associated with market
conditions and the satisfaction of customary closing conditions
related to the proposed public offering, as well as risks and
uncertainties inherent in AzurRx’s business, including those
described in the company's prior press releases and in the periodic
reports it files with the SEC. The events and circumstances
reflected in the company's forward-looking statements may not be
achieved or occur and actual results could differ materially from
those projected in the forward-looking statements. Except as
required by applicable law, the company does not plan to publicly
update or revise any forward-looking statements contained herein,
whether as a result of any new information, future events, changed
circumstances or otherwise.
CONTACT:
AzurRx BioPharma, Inc.
760 Parkside Avenue, Suite 304
Brooklyn, NY 11226
Phone: 646.699.7855
www.azurrx.com
info@azurrx.com
Source: AzurRx BioPharma, Inc